Next Article in Journal
Molecular Dynamics Simulations of Hsp90 with an Eye to Inhibitor Design
Next Article in Special Issue
Strategies To Modulate Heritable Epigenetic Defects in Cellular Machinery: Lessons from Nature
Previous Article in Journal
The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy
Previous Article in Special Issue
A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)
Open AccessArticle

Differential Cellular and Molecular Effects of Butyrate and Trichostatin A on Vascular Smooth Muscle Cells

1
Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne St, Houston, TX 77004, USA
2
Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2012, 5(9), 925-943; https://doi.org/10.3390/ph5090925
Received: 21 July 2012 / Revised: 22 August 2012 / Accepted: 23 August 2012 / Published: 4 September 2012
(This article belongs to the Special Issue Epigenetic Therapies and Biomarkers)
The histone deacetylase (HDAC) inhibitors, butyrate and trichostatin A (TSA), are epigenetic histone modifiers and proliferation inhibitors by downregulating cyclin D1, a positive cell cycle regulator, and upregulating p21Cip1 and INK family of proteins, negative cell cycle regulators. Our recent study indicated cyclin D1 upregulation in vascular smooth muscle cells (VSMC) that are proliferation-arrested by butyrate. Here we investigate whether cyclin D1 upregulation is a unique response of VSMC to butyrate or a general response to HDAC inhibitors (HDACi) by evaluating the effects of butyrate and TSA on VSMC. While butyrate and TSA inhibit VSMC proliferation via cytostatic and cytotoxic effects, respectively, they downregulate cdk4, cdk6, and cdk2, and upregulate cyclin D3, p21Cip1 and p15INK4B, and cause similar effects on key histone H3 posttranslational modifications. Conversely, cyclin D1 is upregulated by butyrate and inhibited by TSA. Assessment of glycogen synthase 3-dependent phosphorylation, subcellular localization and transcription of cyclin D1 indicates that differential effects of butyrate and TSA on cyclin D1 levels are linked to disparity in cyclin D1 gene expression. Disparity in butyrate- and TSA-induced cyclin D1 may influence transcriptional regulation of genes that are associated with changes in cellular morphology/cellular effects that these HDACi confer on VSMC, as a transcriptional modulator. View Full-Text
Keywords: butyrate; trichostatin A; vascular smooth muscle cells; proliferation; cyclin D1; HDAC butyrate; trichostatin A; vascular smooth muscle cells; proliferation; cyclin D1; HDAC
Show Figures

Figure 1

MDPI and ACS Style

Milton, S.G.; Mathew, O.P.; Yatsu, F.M.; Ranganna, K. Differential Cellular and Molecular Effects of Butyrate and Trichostatin A on Vascular Smooth Muscle Cells. Pharmaceuticals 2012, 5, 925-943.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop